IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $15.00 | Buy | Lake Street |
| 11/1/2021 | $15.00 | Outperform | Robert W. Baird |
| 11/1/2021 | Outperform | William Blair | |
| 11/1/2021 | $15.00 | Outperform | Baird |
| 10/22/2021 | $14.00 | Outperform | Cowen & Co. |
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing
RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA
OpenSesame today announced it has appointed Tamar Elkeles, PhD, and Emily Rollins to its Board of Directors. Dr. Elkeles is a highly regarded Chief Human Resources Officer and thought leader, advising globally on Talent, Learning, Human Resources, and Organization Development. Ms. Rollins has served hundreds of companies during her career at Deloitte, where she held various leadership positions in their U.S. Technology, Media, and Telecommunications practice, Audit Innovation and Transformation, and Diversity and Inclusion initiatives. Both executives bring decades of experience in technology, talent, finance, and governance to OpenSesame. Dr. Elkeles has spent 30 years in the human capit
Lake Street initiated coverage of Science 37 with a rating of Buy and set a new price target of $15.00
Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00
William Blair initiated coverage of Science 37 Hldgs with a rating of Outperform
Baird initiated coverage of Science 37 Hldgs with a rating of Outperform and set a new price target of $15.00
Cowen & Co. initiated coverage of Science 37 Hldgs with a rating of Outperform and set a new price target of $14.00
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial
RESEARCH TRIANGLE PARK, N.C., July 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report second quarter 2023 financial results prior to the market open on Tuesday, August 8, 2023. The Science 37 management team will host a conference call to discuss these results on August 8, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13739329 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the inve
RESEARCH TRIANGLE PARK, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended March 31, 2023. "First quarter results reflected continued progress with our key strategic initiatives," stated David Coman, Chief Executive Officer of Science 37. "Our recent actions to reduce our cost structure and increase focus on our unique Metasite solution position us well to drive profitable revenue growth and shareholder value creation." Quarterly Financial Highlights Revenue was $14.1 million for the quarter ended March 31, 2023, a 25% decrease compare
RESEARCH TRIANGLE PARK, N.C., May 01, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report first quarter 2023 financial results prior to the market open on Monday, May 15, 2023. The Science 37 management team will host a conference call to discuss these results on May 15, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13737724 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor re
RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will host a business update conference call prior to the market open on Wednesday, April 12, 2023. The Science 37 management team will host a conference call to discuss the business update on April 12, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Scie
RESEARCH TRIANGLE PARK, N.C., March 06, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter and full year ended December 31, 2022. "Fourth quarter results demonstrated a healthy rebound in bookings and continued efficiency and discipline with our cash resources," stated David Coman, Chief Executive Officer of Science 37. "We remain confident that our strategy positions us well for profitable revenue growth and shareholder value creation ahead." Quarterly Financial Highlights Revenue was $15.9 million for the quarter ended December 31, 2022, a 22% decrease compared to the sa
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report fourth quarter 2022 financial results prior to the market open on Monday, March 6, 2023. The Science 37 management team will host a conference call to discuss these results on March 6, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) using the conference ID 13736111 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investo
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite, announced today that it has acquired the life sciences platform from Vault Health, a national leader in remote diagnostics and COVID testing, to further enhance clinical trial workflow orchestration and data interoperability capabilities of the Science 37 platform. The asset purchase accelerates Science 37's existing development plans for workflow features such as advanced scheduling and investigational product tracking, and data exchange with Electronic Data Capture and Electronic Medical Record systems. As a result, these capabilities will help reduce s
MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company's role in a registrational Phase 3 asthma study, which Science 37 contributed 28% of the total patient enrollment. The FDA evaluated internal processes, technology, data integrity, patien
MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing
MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial
MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing operations in one facility will enable Science 37 to deliver patient recruitment and study conduct support on behalf of clinical trial sponsors with greater consistency, speed, and quality
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed to the recruitment and enrollment of an immunocompromised patient cohort for the sponsor's Phase 3 trial. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 identified, recruited, medically qualified, and enrolled 129 patients across 36 states within an 8-week timeline, averaging 65 patients per month. As the top-enrolling site, Science 37 successfully randomized and trea
RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions. "Enrollment delays can be costly and create immense pressure to deliver results," commented Brian Smith, Senior VP of Project Delivery at Science 37. "Traditionally, study teams address this by starting up more sites and/or adding patient
RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders. Science 37 augmented the recruitment and enrollment activities taking place at study sites nationwide for this ongoing Phase 2 trial evaluating the effects of EP547 in patients with Cholestatic Pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis. The study protocol mandated a highly specific patient population, requir
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation. The nearly two-week review included, but was not limited to, the Science 37 Metasite™ model and internal processes, technology utilized to support each trial, data integrity, efficacy, subject safety, protocol deviations, collaboration across teams, and, most importantly, Principal Investigator oversight. Conducted between February 26 and March 6, 2024, the first-of-its-kind FDA inspection yielded success with no significant issues identified ("No Action Indicated") and no objectionable
Science 37's Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and Companies RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., today announced its selection as winner of the "Clinical Efficiency Innovation Award" in the 8th annual MedTech Breakthrough Awards program. MedTech Breakthrough, an independent market intelligence organization, recognized Science 37 for its transformative solution to clinical research patient recruitment. By leveraging its nationwide medical licensure and AI-powered patient screening capabilities, Science 37's Patient Recruitment solu
RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial. Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 28% of all randomized study participants over a 15-month enrollment window. Science 37 averaged 44 patients enrolled per month, while each of the 55 brick-and-mortar sites supporting the trial enrolled an average of two participants per month. Science 37 delivered an enrollment velocity 22x greater tha
15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)
EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)
EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)
S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)
S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)
S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)
S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)
POS AM - Science 37 Holdings, Inc. (0001819113) (Filer)
POS AM - Science 37 Holdings, Inc. (0001819113) (Filer)
8-K - Science 37 Holdings, Inc. (0001819113) (Filer)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13G/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13G/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13G - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)